Solid Biosciences Inc.

Healthcare · Biotechnology · United States

Last price 6.39 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 685.17M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treat...